Home / Stocks / ABBV

AbbVie (ABBV, Biotechnology) Stock Valuation & Fair Value Significantly overvalued

AbbVie (ABBV, Biotechnology) trades at a blended P/E of 20.9, about 50% above its historical normal valuation, with a forward growth estimate of 16.3% and a PEG of 1.28. Analysts' one-year estimates have been hit 73% of the time.

DATA AS OF 2026-08-21
Blended P/E
20.9
Normal P/E
13.9
PEG
1.28
Fwd growth
16.3%
Div yield
2.6%
RSI (14)
62.0
Neutral

The Street vs SeerForecast

Wall Street's mean price target for ABBV is $276.24 across 29 analysts, 4.3% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from quality business with a solid forward outlook (2026-06-03) to significantly overvalued (2026-08-21).

Price and rating by weekClose moved +15.7 percent from 2026-06-03 to 2026-08-17, with 2 rating changes over 21 recorded weeks.2026-06-03: Quality business with a solid forward outlook, close 215.60 (recalculated)2026-06-10: Quality business with a solid forward outlook, close 223.36 (recalculated)2026-06-14: Quality business with a solid forward outlook, close 226.12 (recalculated)2026-06-16: Quality business with a solid forward outlook, close 220.90 (recalculated)2026-06-21: Quality business with a solid forward outlook, close 214.96 (recalculated)2026-07-02: Significantly overvalued, close 259.22 (recalculated)2026-07-06: Significantly overvalued, close 252.96 (recalculated)2026-07-09: Significantly overvalued, close 248.14 (recalculated)2026-07-12: Quality business with a solid forward outlook, close 246.33 (recalculated)2026-07-13: Quality business with a solid forward outlook, close 246.25 (recalculated)2026-07-14: Quality business with a solid forward outlook, close 243.05 (recalculated)2026-07-20: Quality business with a solid forward outlook, close 253.38 (recalculated)2026-07-22: Quality business with a solid forward outlook, close 253.30 (recalculated)2026-07-25: Quality business with a solid forward outlook, close 259.36 (recalculated)2026-07-27: Quality business with a solid forward outlook, close 256.91 (recalculated)2026-07-31: Quality business with a solid forward outlook, close 250.94 (recalculated)2026-08-03: Quality business with a solid forward outlook, close 250.942026-08-07: Quality business with a solid forward outlook, close 246.04 (recalculated)2026-08-10: Quality business with a solid forward outlook, close 246.042026-08-14: Quality business with a solid forward outlook, close 249.46 (recalculated)2026-08-17: Quality business with a solid forward outlook, close 249.462162492026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 18.6+34%Quality business with a solid forward outlook
2026-06-10P/E 19.2+38%Quality business with a solid forward outlook
2026-06-14P/E 19.2+38%Quality business with a solid forward outlook
2026-06-16P/E 19.2+38%Quality business with a solid forward outlook
2026-06-21P/E 19.2+38%Quality business with a solid forward outlook
2026-07-02P/E 20.7+49%Significantly overvalued
2026-07-06P/E 21.5+55%Significantly overvalued
2026-07-09P/E 21.5+55%Significantly overvalued
2026-07-12P/E 20.4+47%Quality business with a solid forward outlook
2026-07-13P/E 20.4+47%Quality business with a solid forward outlook
2026-07-14P/E 20.4+47%Quality business with a solid forward outlook
2026-07-20P/E 20.9+50%Quality business with a solid forward outlook
2026-07-22P/E 20.9+50%Quality business with a solid forward outlook
2026-07-25P/E 21.1+52%Quality business with a solid forward outlook
2026-07-27P/E 21.1+52%Quality business with a solid forward outlook
2026-07-31P/E 20.8+50%Quality business with a solid forward outlook
2026-08-03P/E 20.4+47%Quality business with a solid forward outlook
2026-08-07P/E 19.7+42%Quality business with a solid forward outlook
2026-08-10P/E 19.8+43%Quality business with a solid forward outlook
2026-08-14P/E 20.1+45%Quality business with a solid forward outlook
2026-08-17P/E 20.0+44%Quality business with a solid forward outlook
2026-08-21P/E 20.9+50%Significantly overvalued ← now

Frequently asked questions

Is AbbVie stock overvalued?

At a blended P/E of 20.9 versus its historical normal P/E of 13.9, AbbVie trades about 50% above its typical valuation, with a PEG of 1.28 on 16.3% forward growth. tickerseer currently rates it significantly overvalued.

What is AbbVie's fair value and PEG?

AbbVie trades at a blended P/E of 20.9 against a historical normal P/E of 13.9, a PEG of 1.28, and a forward growth estimate of 16.3%.

Has tickerseer's rating of AbbVie changed?

tickerseer's rating moved from quality business with a solid forward outlook (2026-06-03) to significantly overvalued (2026-08-21).

What is the analyst price target for AbbVie?

The mean Wall Street price target for AbbVie is $276.24 across 29 analysts, 4.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ABBV free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.